{"id":795745,"date":"2024-12-18T08:06:40","date_gmt":"2024-12-18T13:06:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/"},"modified":"2024-12-18T08:06:40","modified_gmt":"2024-12-18T13:06:40","slug":"alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/","title":{"rendered":"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d or \u201cthe Company\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025.<\/p>\n

ASPEN-06 is a randomized, multi-center, international trial (NCT05002127)<\/a> evaluating evorpacept, ALX Oncology\u2019s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA\u00ae\u00a0(ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric\/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.<\/p>\n

The updated results from the ASPEN-06 study will be detailed in the following oral presentation:<\/p>\n

\n Title: <\/strong>
\n
\n Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2\/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric\/gastroesophageal cancer (GC)<\/u>
\n <\/a>
\n
\n Abstract Number:<\/strong> 332
Presenter:<\/strong> Kohei\u00a0Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in Japan
Presentation Date and Time:<\/strong> Thursday, January 23, 2025, from 9:15 a.m. \u2013 10:00 a.m. PST
Session Information:<\/strong> Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach
Location:<\/strong> Level 2 Ballroom<\/p>\n

Copies of the presentations will be available on the Publications<\/u><\/a> section of ALX Oncology\u2019s website following presentation at the meeting.<\/p>\n

\n About ALX Oncology<\/strong>
\n
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com<\/u><\/a> and on LinkedIn @ALX Oncology<\/u><\/a>.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Company Contact:\r\nCaitlyn Doherty, Manager, Corporate Communications, ALX Oncology\r\ncdoherty@alxoncology.com\r\n(650) 466-7125\r\n\r\nMedia Contact:\r\nAudra Friis, Sam Brown, Inc.\r\naudrafriis@sambrown.com\r\n(917) 519-9577<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d or \u201cthe Company\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025. ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology\u2019s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA\u00ae\u00a0(ramucirumab) and paclitaxel (collectively, TRP) … <\/p>\n
Continue reading “ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-795745","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d or \u201cthe Company\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025. ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology\u2019s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA\u00ae\u00a0(ramucirumab) and paclitaxel (collectively, TRP) … Continue reading "ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-18T13:06:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium\",\"datePublished\":\"2024-12-18T13:06:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/\"},\"wordCount\":372,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/\",\"name\":\"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=\",\"datePublished\":\"2024-12-18T13:06:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d or \u201cthe Company\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025. ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology\u2019s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA\u00ae\u00a0(ramucirumab) and paclitaxel (collectively, TRP) … Continue reading \"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-18T13:06:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium","datePublished":"2024-12-18T13:06:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/"},"wordCount":372,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/","name":"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=","datePublished":"2024-12-18T13:06:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDY1MSM2NjQxNTA4IzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-present-updated-results-from-phase-2-aspen-06-clinical-trial-of-evorpacept-in-patients-with-her2-positive-gastric-cancer-in-oral-presentation-at-2025-asco-gastrointestinal-cancers-symp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=795745"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795745\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=795745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=795745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=795745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}